WZWei Zhang

Wei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Zhang has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Ti Zhang

    Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China

    9 shared publications
  • Qiang Li

    Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

    8 shared publications
  • Qiang Wu

    8 shared publications
  • Yingying Wang

    Tianjin Medical University Cancer Institute and Hospital

    7 shared publications
  • Tianqiang Song

    Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China

    6 shared publications
  • Huikai Li

    5 shared publications

Latest Publications

  • Open Access

    Integrated multi-omics profiling identifies an immunotherapy vulnerable and prognostic associated subtype in Cholangiocarcinoma

    by Lu Chen, Yuchao He, Hong Su, Xiangdong Tian, Haotian Liao, Dongming Liu, Meng Zhao, Huichuan Sun, Lisha Qi, Manqing Cao, et al.

    Introduction: Cholangiocarcinoma (CCA) is an aggressive malignancy with poor prognosis and limited treatment options. Molecular heterogeneity and the tumor immune microenvironment play crucial roles in CCA progression and therapeutic response, but comprehensive stratification remains insufficient for guiding treatment decisions. Methods: This study performed integrated multi-omics profiling as well as immunohistochemical validation on 424 CCA patients. Multi-dimensional data, including genomic, epigenomic, transcriptomic, and immune profiling, were analyzed to identify clinically relevant molecular subtypes. Results: Four distinct molecular subtypes of CCA were identified, each exhibiting unique clinical and immunological features: C1 (Proliferation): Driven by TP53/KRAS mutations and CpG island methylator phenotype (CIMP+) hypermethylation, showing Th17 cells infiltration and poor outcomes; C2 (Immune-Suppressed Macro_LYVE1, (ISM_LYVE1)): Stroma-rich with LYVE1⁺ macrophages and epithelial-mesenchymal transition (EMT) activation; C3 (Immune-Activated Macro_C1QC (IAM_C1QC)): Enriched in C1QC⁺ macrophages, CD8⁺ T-cells, and metabolic pathways, highly responsive to immune checkpoint blockade (75% Overall Response Rate (ORR)); C4 (Immune Exclusion, (IE)): FGFR2-altered and IDH1-mutant, with an immunologically-cold phenotype. Conclusion: We validated ATP2B1 as a novel prognostic biomarker and developed a 160-gene classifier for subtype prediction. The C3 subtype’s exceptional immune checkpoint blockade (ICB) response, independent of conventional biomarkers (PD-L1/microsatellite instability (MSI)/tumor mutational burden (TMB)), highlights the clinical utility of this classification system in guiding precision immunotherapy for CCA.


  • Open Access

    Low expression of miR125a-5p predicts sensitivity to sorafenib by upregulating STAT3 and HTATIP2 in hepatocellular carcinoma

    by Hongyuan Zhou, Lu Yang, Yu Wang, Qin Zhang, Zewu Zhang, Yingying Wang, Zhaolong Pan, Junbo Cao, Dongyang Li, Chen Liu, et al.

    Background Sorafenib is a standard of care for systemic therapy of hepatocellular carcinoma (HCC). Further personalized treatment with sorafenib is warranted. The current study aims to identify predictive biomarkers for the efficacy of sorafenib and investigate the underlying mechanism. Methods MiRNA array was performed in formalin-fixed paraffin-embedded tumour from patients who received adjuvant sorafenib therapy after liver resection, including patients who had tumor recurrence within one year and patients without tumor recurrence after liver resection. In situ hybridization (ISH) was performed to evaluate the expression of miR-125a-5p, and the association of miR125a-5p with overall survival (OS) and recurrence free survival (RFS) was evaluated. LM3 with miR125a-5p overexpression and SMMC7721 with miR125a-5p knockdown were constructed using lentiviruses respectively. The sensitivity to sorafenib treatment were studied by in vitro CCK8 assay and in vivo xenograft tumor model. RNA-seq, luciferase reporter assay, real-time PCR and Western blot assays were performed to elucidate the underlying mechanism. Results MiR125a-5p was among the most significantly changed microRNAs and low expression of miR125a-5p was associated with increased sensitivity to sorafenib. In situ hybridization and survival analysis found that higher miR125a-5p was associate with improved OS and RFS for HCC patients after liver resection. We overexpressed miR125a-5p in LM3 HCC cells and knockdown miR-125a-5p in SMMC7721, respectively, and confirmed that miR125a-5p overexpression caused sorafenib resistance both in vivo and in vitro, while miR125a-5p suppression led to sensitivity to sorafenib treatment. RNAseq and pathway analysis revealed that STAT3 pathway was downregulated by miR125a-5p. STAT3 was also confirmed as a target of miR125a-5p by TargetScan prediction, and both STAT3 and HTATIP2 were downregulated by miR125a-5p in in-vitro experiment. Conclusion Low expression of miR125a-5p predicted sorafenib sensitivity by upregulating STAT3 and HTATIP2.

  • Open Access

    Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma

    by Kailiang Qiao, Jingxia Han, Haohao Zhang, Yinan Li, Xiaohui Hou, Yan Jia, Yujie Sun, Huan Wang, Zheng Xu, Haoyang Liu, et al.


  • Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy

    by Xiang Dong, Zewu Zhang, Qin Zhang, Lu Chen, Guangtai Cao, Chen Liu, Tianqiang Song, Wei Lu, Wei Zhang

    Purpose The combination of gemcitabine-based chemotherapy and immune checkpoint inhibitors has a good efficacy in advanced biliary tract cancer (BTC). The multi-target TKI lenvatinib and NGS-guided targeted therapy are also promising in BTC treatment. This study aimed to explore the performance of GemOX plus sintilimab and TKI (either lenvatinib or by NGS-guided targeted therapy) for local advanced or metastatic BTCs. Methods This prospective single-arm study included patients with local advanced or metastatic BTCs and applied intravenous infusion of standard GemOX plus sintilimab and lenvatinib (no targetable gene alterations) or targeted therapy based on NGS (olaparib for BRCA1/2 mutation, dasatinib for IDH1/2 mutation, afatinib for EGFR amplification, lenvatinib for PDGFR and KIT mutation, and lenvatinib for FGFR/KIT mutation). Results From November 2020 to December 2021, 22 patients BTCs (6 GBC, 14 iCCA, 1 pCCA and 1 dCCA cases) were enrolled, with an average age of 58.4 years. Partial response (PR) was achieved in 10 cases, stable disease (SD) in 9 cases and progression disease (PD) in 3 cases (13.6%). The objective response rate (ORR) was 45.5%, and the disease control rate (DCR) was 86.4%. During the treatment, the incidence of adverse reactions was 81.8%, and the incidence of grade 3/4 adverse events was 9.09%. For 14 patients with NGS, 5 patients were treated by targeted therapy and there were 1 SD and 4 PR cases. For four patients with positive PD-L1 expression, the ORR was 100%. While among the three patients with super-progression markers such as RET, MDM2 and FGF14/STK24, there were two SD and one PD cases. Conclusion In patients with advanced BTCs, the combination of GemOX plus sintilimab and lenvatinib or NGS-guided targeted therapy showed promising ORR and DCR, especially for the patients with positive PD-L1 expression and targetable gene alterations.


  • Open Access

    Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives

    by Wei Zhang, Tianqiang Song

    Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives Wei Zhang, Tianqiang Song


  • Open Access

    High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma

    by Bingqi Ma, Huijuan Meng, Ye Tian, Yingying Wang, Tianqiang Song, Ti Zhang, Qiang Wu, Yunlong Cui, Huikai Li, Wei Zhang, et al.

    Herpesvirus entry mediator (HVEM) displays dual signals in T‑cell activation according to the ligands and intracytoplasmic effectors it interacts with. High HVEM expression may play an immunosuppressive role in several malignancies. The present study investigated the clinical impact of HVEM on intrahepatic cholangiocarcinoma (ICC), including its prognostic value, and association with clinicopathological features and immune status. The clinical data of 102 consecutive patients with ICC who underwent surgical treatment from January 2012 to December 2017 were collected. The expression of HVEM and different types of tumor‑infiltrating lymphocytes (TILs) were investigated in ICC tissue samples by immunohistochemical staining. HVEM expression was detected in the tumor tissues of 92 (90.2%) patients with ICC. Patients with high HVEM expression were more likely to have increased peripheral blood lymphocyte (PBL) concentrations (P=0.031), decreased CEA (P=0.036), low TNM stage (P=0.043) and high frequencies of small‑duct histological type (P=0.021) and BAP1 retained expression (P=0.010). Survival analysis showed that high HVEM expression was a favorable independent predictor of overall postoperative survival (P=0.034, hazard ratio=0.486, 95% confidence interval=0.249‑0.945). In addition, no significant association of HVEM expression with CD4+ (P=0.512), CD8+ (P=0.750) or CD45RO+ (P=0.078) TILs was identified in the ICC tissues. These results indicate that HVEM may serve as a favorable prognostic marker for ICC. Furthermore, co‑stimulatory signals from HVEM may play a dominant role in the progression of ICCs, which can be explained by an increase in the number of PBLs rather than a change in the number of TILs. However, the function of the HVEM network in ICC progression is complex and requires further study.


  • Systemic treatment of advanced or recurrent biliary tract cancer

    by Wei Zhang, Hongyuan Zhou, Yingying Wang, Zewu Zhang, Guangtai Cao, Tianqiang Song, Ti Zhang, Qiang Li

    Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies


  • Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers

    by Wei Zhang, Junping Shi, Yingying Wang, Hongyuan Zhou, Zewu Zhang, Zhiqiang Han, Guanghao Li, Bo Yang, Guangtai Cao, Yan Ke, et al.

    Background Chemotherapy is a standard regimen for advanced or relapsed biliary tract cancer (BTC) with a 5-year overall survival (OS) rate of approximately 5% and a median OS of less than a year. Targeted therapies and immunotherapy aimed at providing more personalized treatments for BTCs have been tested. The objective of this study was to evaluate the effects of targeted therapy and immunotherapy on advanced BTC patients. Methods Twenty-four advanced/relapsed BTC patients were enrolled and examined with next-generation sequencing (NGS). Eight of them received NGS-guided targeted or immunotherapy, and the other 16 patients underwent routine chemotherapy. Comparison analysis of OS and objective response rate (ORR) was performed. Results IDH1, BRCA2, MAP2K1, and BRAF (V600E) were the major actionable genes mutated in this cohort. Patients who received NGS-guided therapy exhibited higher OS (not achieved vs. 6.5 months, p < 0.001) and ORR (87.5% vs. 25%, p < 0.001) than those without targetable mutations and who received first-line chemotherapy. BTCs harboring mutations in IDH1, ATM/BRCA2, or MAP2K1/BRAF (V600E) received treatment with dasatinib, olaparib, or trametinib, respectively. Three of the patients had high tumor mutation burden (TMB-H) and were treated with immune-checkpoint inhibitors and chemotherapy. All these patients achieved complete response or partial response. Conclusions NGS-guided targeted therapy and immunotherapy are promising personalized therapies for advanced or relapsed BTCs. TMB is a useful biomarker for predicting immunotherapy efficacy.


  • Open Access

    Serum CA19-9 Level is Correlated with Liver Inflammation, Cirrhosis, and Poor Prognosis after Curative Resection in Hepatitis B-related Hepatocellular Carcinoma

    by Wei Zhang, Ying-Ying Wang, Bo Yang, Lu Chen, Ze-Wu Zhang, Guang-Tai Cao, Xiao-Yu Huang, Guang-Hao Li, Hui-Kai Li, Yun-Long Cui, et al.

    Background: The relationship between serum carbohydrate antigen 19-9 (CA19-9) and hepatocellular carcinoma (HCC) is unclear. To explore the prognostic value of preoperative CA19-9 in α-fetoprotein (AFP)-positive and -negative HCC with hepatitis B virus (HBV) background (HBV-HCC).Methods: We evaluated HBV-HCC patients who underwent curative resection (Cohort 1). Recurrence-free survival (RFS) and overall survival (OS) were assessed, and the clinicopathological characteristics were compared according to a CA19-9 cutoff of ≥ 39 U/ml. Immunohistochemical staining of CA19-9 in HCC tumor tissue and background liver were quantified in another cohort of 216 patients with resected HCC (Cohort 2). Immunohistochemical staining or serum CA19-9 level was also compared between patients with intrahepatic cholangiocarcinoma (ICC) (Cohort 3).Results: In Cohort 1, CA19-9 ≥ 39 U/ml was an independent risk factor for RFS (HR=1.507, 95% CI=1.087-2.091, p=0.014) and OS (HR=1.646, 95% CI=1.146-2.366, p=0.007) in both AFP-positive and AFP-negative patients. CA19-9 ≥ 39 U/ml was also associated with significantly higher incidence of macrovascular invasion compared with CA19-9 < 39 U/ml (23.0% vs. 7.2%, p=0.002), elevated aminotransferase and aspartate aminotransferase to platelet ratio index, and lower albumin. In contrast, no association was found between CA19-9 and systemic inflammation. CA19-9 expression was found exclusively in the background liver but not in HCC tumor cells. In contrast, tumor tissue was the main source of CA19-9 in ICC patients.Conclusions: CA19-9 ≥ 39 U/ml was associated with lower OS and RFS in both AFP-positive and negative HCC patients. CA19-9 is secreted by the background liver but not by tumor cells. Thus, CA19-9 is a prognostic marker for liver inflammation and cirrhosis in HCC.

  • Open Access

    Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma

    by Bingqi Ma, Huijuan Meng, Ye Tian, Yingying Wang, Tianqiang Song, Ti Zhang, Qiang Wu, Yunlong Cui, Huikai Li, Wei Zhang, et al.

    Background: Isocitrate dehydrogenase 1/2 (IDH1/2), BAP1, ARID1A and PBRM1 have been reported as the most frequent mutant genes in intrahepatic cholangiocarcinoma (ICC), and their relationships with clinicopathological features and prognosis were researched in this study. Methods: We collected clinical data of 130 ICC patients from January 2012 to December 2017. The IDH1/2 mutation and loss of BAP1, ARID1A and PBRM1 expressions were detected by DNA sequencing or immunohistochemical methods, and histological subtype of ICCs was determined by hematoxylin-eosin, Alcian blue and S100P staining. Results: IDH1/2 mutation was related to decreased preoperative serum total bilirubin (P = 0.039), ferritin (P = 0.000) and higher histological differentiation (P = 0.024), and was associated with prolonged disease-free survival (P = 0.009) and a trend toward increased overall survival (P = 0.126) in small duct type of ICCs. Immunohistochemical staining results of MsMab-1 were generally consistent with DNA sequencing for IDH1/2 mutant in ICCs (κ = 0.691). Only BAP1 expression loss was correlated to prolonged disease-free survival (P = 0.031) and overall survival (P = 0.041) in large duct type of ICCs. Conclusions: IDH1/2 mutation is a favorable predictor and may be related to iron metabolism in small duct type of ICCs. Furthermore, we suggest that the detection of IDH1/2 mutation is indispensable to determine targeted therapy in small duct type ICCs, while it is not necessary in large duct of ICCs. MsMab-1 is a relatively effective multi-specific antibody against IDH1/2 mutant in ICCs. BAP1 expression loss was correlated with improved prognosis only in large duct type ICCs.